Business Context and Reporting Period
Indaptus Therapeutics, Inc. filed a Form 8-K reporting the results of its 2022 annual meeting of stockholders held on September 29, 2022. The report was signed on September 30, 2022. The company’s common stock trades on the Nasdaq Capital Market under the symbol INDP.
Key Financial Metrics
This filing is limited to corporate governance and voting matters. It does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balances, or other financial performance metrics.
Material Changes Versus the Prior Comparable Period
No operating or financial-period comparison is presented. The filing reports that all matters submitted to stockholders were approved and that Hila Karah and Mark J. Gilbert, M.D. were elected as directors to serve until the 2025 annual meeting or until their successors are elected and qualified.
Meeting Results, Outlook, and Other Matters
- A quorum of 4,187,016 shares was represented in person or by valid proxy.
- Executive compensation was approved on an advisory basis, with 2,088,233 votes for, 185,874 against, and 14,371 abstentions; broker non-votes totaled 1,898,538.
- Stockholders recommended, on an advisory basis, that future executive compensation votes occur every three years. The board adopted this three-year frequency on September 30, 2022, until the next required frequency vote.
- Haskell & White LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 4,116,792 votes for, 11,221 against, and 59,003 abstentions.
- No management guidance, business outlook, material contingency, financing transaction, or unusual financial item is disclosed.
Important Facts to Verify
- Confirm the board’s implementation of triennial advisory votes on executive compensation and the timing of the next required frequency vote.
- Review the company’s subsequent filings for financial condition, financing needs, liquidity, and operating developments, which are not addressed in this 8-K.
- Note the substantial broker non-votes in the director and executive compensation proposals when assessing voting support.
- Verify the appointment and continued engagement of Haskell & White LLP in subsequent annual or periodic filings.